The role of receptors in prostate cancer

Advances in Clinical Chemistry

Volumn 35, Issue , 2001, Pages 101-160

  Prinsloo, Sophia E ^a   Van Aswegen, Casper H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ESTROGEN; GROWTH FACTOR RECEPTOR; STEROID RECEPTOR;

CHEMISTRY; GENETICS; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW; RISK FACTOR;

ANDROGENS; BIOLOGICAL MARKERS; ESTROGENS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CELL SURFACE; RECEPTORS, GROWTH FACTOR; RECEPTORS, STEROID; RISK FACTORS;

EID: 0034565520     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-2423(01)35016-3     Document Type: Review

References (353)

1. Akakura K. Akimoto S. Furuya Y. Ito H. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate Eur Urol. 33 1998 567 571
2. Alberts B. Bray D. Lewis J. Raff M. Roberts K. Watson J.D. Molecular Biology of the cell 1994 Garland New York & London
3. Allegretto E.A. McClung M.R. Lazarchik S.B. Clem D.L. Kerner S.A. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effect of metabolism J. Biol. Chem. 268 1993 26625 26633
4. Anderson S.O. Wolk A. Berghstrom R. Adami H.O. Engholm G. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers J. Natl. Cancer Inst. 89 1997 385 389
5. Angelloz-Nicoud P. Binoux M. Autotrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3) Endocrinology 136 1995 5485 5492
6. Angelloz-Nicoud P. Harel L. Binoux M. Recombinant insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases Growth Regul. 6 1996 130 136
7. Arai Y. Yoshiki T. Yoshida O. c-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer Prostate 30 1997 195 201
8. Bare R.L. Torti F.M. Endocrine therapy of prostate cancer K.A. Foon H.B. Muss Hormonal Therapies of Cancer 1998 Kluwer Boston 69 87
9. Barrack E.R. TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity Prostate 31 1997 61 70
10. Barrett-Connor E. Garland C. McPhillips J.B. Khaw K.T. Wingard D.L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer Cancer Res. 50 1990 169 173
11. Benbassat C.A. Maki K.C. Unterman T.G. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: Relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures J. Clin. Endocrinol. Metab. 82 1997 1484 1491
12. Bishop M.C. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br. J. Urol. 78 1996 921 927
13. Bissada N.K. Kaczmarek A.T. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of dietylstilbestrol J. Urol. 153 1995 1944 1945
14. Blok L.J. de Ruiter P.E. Brinkmann A.O. Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding Biochemistry 37 1998 3850 3857
15. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1 Endocrinology 138 1997 1491 1497
16. Bosland M.C. Dreef-Van Der Meulen H.C. Sukumar S. Ofner P. Leav L. Multistage prostate carcinogenesis: the role of hormones Princess Takamatsu. Symp. 22 1991 109 123
17. Brass A.L. Barnard J. Patai B.L. Salvi D. Rukstafs D.B. Androgen upregulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen source receptor Cancer Res. 55 1995 3197 3203
18. Braun M.M. Helzlsouer K.J. Hollis B.W. Comstock G.W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States) Cancer Causes Control 6 1995 235 239
19. Brawer M.K. Prostate-specific antigen: Current status C. A. Cancer J. Clin. 49 1999 264 281
20. Brinkmann A.O. Jenster G. Kuiper G.G. Ris C. van Laar J.H. The human androgen receptor: structure/function relationship in normal and pathological situations J. Steroid Biochem. Mol. Biol. 41 1992 361 368
21. Brolin J. Anderson L. Ekman P. Steroid receptor profile and receptors stability in subfractions of human prostate tissues. Critical aspects on microassays Urol. Res. 19 1991 327 331
22. Brolin J. Skoog L. Ekman P. Immunchistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue Prostate 20 1992 281 295
23. Burfeind P. Chernicky C.L. Rininsland F. Ilan J. Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor invasion by rat prostate cancer cells in vivo Proc. Natl. Acad. Sci. (USA) 93 1996 7263 7268
24. Campbell M.J. Reddy G.S. Koeffler H.P. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects J. Cell. Biochem. 66 1997 413 425
25. Campbell M.J. Elstner E. Holden S. Uskokovic M. Koeffler H.P. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafloride vitamin D3 analogue involves the induction of p21 waft, p27kip and E-cadherin J. Mol. Endocrinol. 19 1997 15 27
26. Campbell M.J. Park S. Uskokovic M.R. Dawson M.I. Koeffler H.P. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog Endocrinology 139 1998 1972 1980
27. Carrubba G. Pfeffer U. Fecarotta E. Coviello D.A. D'Amato E. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cells Cancer Res. 54 1994 1190 1193
28. Carstens R.P. Eaton J.V. Krigman H.R. Walther P.J. Garcia-Blanco M.A. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R-2) in human prostate cancer Oncogene 15 1997 3059 3065
29. Castagnetta L.A. Miceli M.D. Sorci C.M.G. Pfeffer U. Farruggio R. Growth of LNCaP human prostate cells is stimulated by estradiol via its own receptor Endoocrnnology 136 1995 2309 2319
30. Cerhan J.R. Turner J.C. Lynch C.F. Rubenstein L.M. Lemke J.H. Association of smoking, body mass, and physical activity with risk of prostate cancer in the low 65+ Rural Health study (United States) Cancer Causes Control 8 1997 229 238
31. Chamberlain N.L. Driver E.D. Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function Nucleic Acids Res. 22 1994 3181 3186
32. Chang A. Yeap B. Davis T. Blum R. Hahn R. Double-blind, randomized study of primary hormone treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol J. Clin. Oncol. 14 1996 2250 2257
33. Chan J.M. Stampfer M.J. Ma J. Rimm E.B. Willett W.C. Giovannucci E.L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States Cancer Epidem. Biomarkers Prev. 8 1999 893 899
34. Chang W.Y. Prins G.S. Estrogen receptor-β: Implications for the prostate gland Prostate 40 1999 115 124
35. Choong C.S. Kemppainen J.A. Zhou Z.X. Wilson E.M. Reduced androgen receptor gene expression with first exon CAG repeat expansion Mol. Endocrinol. 10 1996 1527 1535
36. Chung T.D. Yu J.J. Spiotto M.T. Bartkowski M. Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer Prostate 38 1999 199 207
37. Cohen D.W. Simak R. Fair W.R. Melamed J. Scher H.I. Cordon-Cardo C. Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues J. Urol. 152 1994 2120 2124
38. 3-receptor heterodimers with high affinity Mol. Cell Endocrinol. 113 1995 89 98
39. Connolly J.M. Rose D.P. Secretion of epidermal growth factor and related polypeptides by the DU-145 human prostate cancer cell line Prostate 15 1989 177 186
40. Connolly J.M. Rose D.P. Regulation of DU-145 human prostate cancer cell by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop Prostate 24 1994 167 175
41. Conover C.A. Perry J.E. Tindall D.J. Endogenous cathepsin D-mediated hydrolysis of insuline-like growth factor-binding proteins in cultured human prostatic carcinoma cells J. Clin. Endocrinol. Metab. 80 1995 987 993
42. Cooke P.S. Young P. Hess R.A. Cunha G.R. Estogen receptors expression in developing epididymis, efferent ductules and other male reproductive tracts Endocrinology 128 1991 2874 2879
43. Corder E.H. Friedman G.D. Vogelman J.H. Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepoandrosterone: Risk of prostate cancer in black and white men Cancer Epidemiol. Biomarkers Prev. 4 1995 655 659
44. Cox R.L. Crawford E.D. Estrogens in the treatment of prostate cancer J. Urol. 154 1995 1991 1998
45. (11) Crowley C.W. Cohen R.L. Lucas B.K. Lai G. Shuman M.A. Levinsons A.D. Prevention of metastasis by inhibition of the urokinase receptor Proc. Natl. Acad. Sci. (USA) 90 1993 5021 5025
46. Culig Z. Hobisch A. Cronauer M.V. Radmayr C. Trapman J. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor and epidermal growth factor Cancer Res. 54 1995 5474 5478
47. Culig Z. Hobisch A. Hittmair A. Peterziel H. Radmayr C. Hyperactive androgen receptor in prostate cancer: What does it mean for new therapy concepts? Histol. Histohathol. 12 1997 781 786
48. Culig Z. Hobisch A. Cronauer M.V. Cato A.C. Hittmair A. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol. Endocrinol. 7 1993 1541 1550
49. Culig Z. Stober J. Gast A. Peterziel H. Hobisch A. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone Cancer Detect. Prevent. 20 1996 68 75
50. Dahiya R. Boyle B. Park H.D. Kurhanewich J. Macdonald J.M. Narayan P. 13- Cis -retinoic acid-mediated growth inhibition of DU-145 human prostate cells Biochem. Mol. Biol. Int. 32 1994 1 12
51. Dahiya R. Park H.D. Cusick J. Vessella R.L. Fourrier G. Narayan P. Inhibition of tumorigenic potential and prostate-specific antigen in LNCaP human prostate cancer cell line by 13- cis -retinoic acid Int. J. Cancer 59 1994 126 132
52. Dalal R. Djakiew D. Molecular characterization of neutrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate Mol. Cell. Endocrinol. 134 1 1997 15 22
53. Dalu A. Haskell J.F. Coward L. Lamartiniere C.A. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate Prostate 37 1998 36 43
54. Damber J.E. Landstrom M. Bergh A. Tomic R. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma Scand. J. Ural. Nephrol. Suppl. 110 1988 145 148
55. Damon S.E. Maddison L. Ware J.L. Plymate S.R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation Endocrinology 139 1998 3456 3464
56. Daniell H.W. A better prognosis for obese men with prostate cancer J. Urol. 155 1996 220 225
57. Davies P. Eaton C.L. Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate Prostate 14 1989 123 132
58. Déchaud H. Lejeune H. Garoscio-Cholet M. Mallein R. Pugeat M. Radioimmunoassay of testosterone not bound to sex-steroid-binding protein in plasma Clin Chem. 35 1989 1609 1614
59. De Jager C. Bornman M.S. Van der Horst G. The effect of p-nonylphenol, an environmental toxicant with oestrogenic properties, on fertility potential in adult male rats Andrologia 31 1999 99 106
60. De la Taille A. Hayek O.R. Buttyan R. Bagiella E. Burchardt M. Katz A.E. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients BJU Int. 84 1999 845 850
61. De Vere White R. Meyers F. Chi S.G. Chamberlain S. Siders D. Human androgen receptor expression in prostate cancer following androgen ablation Eur. Urol. 31 1997 1 6
62. De Vos S. Holden S. Heber D. Elstner E. Binderup L. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cells lines Prostate 31 1997 77 83
63. Delsite R. Djakiew D. Anti -proliferatioe effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines J. Androl. 17 1996 481 490
64. Demark-Wahnefried W. Conaway M.R. Robertson C.N. Mathias B.J. Anderson E.E. Paulson D.F. Anthropometric risk factors for prostate cancer Nutr Cancer 28 1997 302 307
65. Denis L. Morton M.S. Griffiths K. Diet and its preventive role in prostatic disease Eur. Urol. 35 1999 377 387
66. Dhom G. Seitz G. Wernert N. Histology and immunohistochemistry studies in prostate cancer Am. J. Clin. Oncol. 11 1988 S37 S42
67. DiPaola R.S. Zhang H. Lambert G.H. Meeker R. Licitra E. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) N. Engl. J Med. 339 1998 785 791
68. Dionne C.A. Camoratto A.M. Jani J.P. Emerson E. Neff N. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587) Clin. Cancer Res. 4 1998 1887 1898
69. (Suppl) Di Sant' Agnese P.A. Neuroendocrine differentiation in prostatic carcinoma Prostate 8 1998 74 79
70. Douglas T.H. Moul J.W. Applications of neural networks in urologic oncology Semin. Urol. Oncol. 16 1998 35 39
71. Dunning W.F. Prostatic cancer in the rat Monogr Natl. Cancer Inst. 12 1963 351 369
72. Edwards A. Hammond H.A. Jin L. Caskey C.T. Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups Genomics 12 1992 241 253
73. Ehara H. Koji T. Deguchi T. Yoshii A. Nakano M. Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry Prostate 27 1995 304 313
74. Ekman P. Brolin J. Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma Prostate 18 1991 147 153
75. Ekman P. Barrack E.R. Greene G.L. Elwood V.J. Walsh P.C. Estrogen receptors in human prostate: Evidence for multiple binding sites J. Clin. Endocrinol. Metab. 57 1983 166 176
76. Elo J.P. Harkonen P. Kyllonen A.P. Lukkarinen O. Poutanen M. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer Cancer Res. 7 1997 3356 3359
77. Emtage L.A. Dunn P.J. Rowse A.D. Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation Br. J Ural. 63 1989 627 633
78. Enmark E. Pelto-Huikko M. Grandien K. Lagercrantz S. Lagercrantz J. Human estrogen receptor β-gene structure, chromosomal localisation, and expression pattern J. Clin. Endocrinol. Metab. 82 1997 4258 4265
79. Esquenet M. Swinnen J.V. Heyns W. Verhoeven G. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids J. Steroid Biochem. Mol. Biol. 62 1996 391 399
80. Evans C.P. Elfman F. Parangi S. Conn M. Cunha G. Shuman M.A. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade Cancer Res. 57 1997 3594 3599
81. Faure C. Pimoule C. Vallencien G. Langer S.Z. Graham D. Identification of a 1-adrenoceptor subtypes present in the human prostate Life Sci. 54 1994 1595 1605
82. Fazioli F. Blasi F. Urokinase-type plasminogen activator and its receptor: New targets for antimetastatic therapy? TiPS 15 1994 25 29
83. Feldman D. Skowronski R.J. Peehl D.M. Vitamin D and prostate cancer Adv. Exp. Med. Biol. 375 1995 53 63
84. Feng S. Wang F. Matsubara A. Kan M. McKeehan W.L. Fibroblast growth factor receptor-2 limits and receptor-1 accelerates tumorigenicity of prostate epithelial cells Cancer Res. 57 1997 5369 5378
85. Figueroa J.A. De Raad S. Tadlock L. Speights V.O. Rinehart J.J. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer J. Urol. 159 1998 1379 1383
86. Figueroa J.A. Lee A.V. Jackson J.G. Yee D. Proliferation of cultured human prostate cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop J. Clin. Endocrinol. Metab. 80 1995 3476 3482
87. Five R.S. Sledge G.W. Jr Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro Cancer Lett. 120 1997 65 69
88. Fox S.B. Persad R.A. Coleman N. Day C.A. Silcocks P.B. Collins C.C. Prognostic value of c-erbB-2 and epidermal growth factor in stage A1 (Tla) prostatic adenocarcinoma Br. J. Urol. 74 1994 214 220
89. Fudge K. Bostwick D.G. Stearns M.E. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia Prostate 29 1996 282 286
90. Fudge K. Wang C.Y. Steams M.E. Immunohistocheminstry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas Mod. Pathol. 75 1994 549 554
91. Fujimoto N. Yeh S. Kang H.Y. Inui S. Chang H.C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate J. Biol. Chem. 274 1999 8316 8321
92. Furuya Y. Akimoto S. Akakura K. Ito H. Smoking and obesity in relation to the etiology and disease progression of prostate cancer in Japan Int. J. Urol. 5 1998 134 137
93. Gaddipati J.P. McLeod D.G. Heidenberg H.B. Sesterhenn I.A. Finger M.J. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res. 54 1994 2861 2864
94. Gail M.H. Costantino J.P. Bryant J. Croyle R. Freedman L. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer J. Nad. Cancer Inst. 91 1999 1829 1846
95. Gann P.H. Ma J. Hennekens C.H. Hollins B.W. Haddad J.G. Stampfer M.J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer Cancer Epidemiol. Biomarkers Prev. 5 1996 121 126
96. Garnick M.B. The dilemmas of prostate cancer Sci. Am. 270 1994 52 59
97. Geliebter J. Tiwari R. Wu J.M. PC-SPES in prostate cancer N. Engl. J. Med. 340 1999 566 568
98. George D.J. Dionne C.A. Jam J. Angeles T. Murakata C. Sustained in vivo regression of Dunning H rat prostate cancer treated with combinations of androgen ablation and trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Res. 59 1999 2395 2401
99. Gerdes M.J. Larsen M. McBride L. Dang T.D. Lu B. Rowley D.R. Localization of transforming growth factor beta-1 and type II receptor in developing normal prostate and carcinoma tissues J. Histochem. Cytochem. 46 1998 379 388
100. Getzenberg R.H. Pienta K.J. Cofey D.S. The tissue matrix: Cell dynamics and hormone action Endocr Rev. 11 1990 399 417
101. Getzenberg R.H. Light B.W. Lapco P.E. Konety B.R. Nangia A.K. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system Urology 51 1997 999 1006
102. Giguere V. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoie signalling Endocr. Rev. 15 1994 61 79
103. (Suppl) Giles G. Ireland P. Diet, nutrition and prostate cancer Int. J Cancer 10 1997 13 17
104. Giovannucci E. Ascherio A. Rimm E.B. Stampfer M.J. Golditz G.A. Willet W.C. Intake of carotenoids and retinol in relation to risk of prostate cancer J. Natl. Cancer Inst. 87 1995 1767 1776
105. Giovannucci E. Clinton S.K. Tomatoes, lycopene, and prostate cancer Proc. Soc. Exp. Biol. Med. 218 1998 129 139
106. Giovannucci E. Leitzmann M. Spiegelman D. Rimm E.B. Colditz G.A. A prospective study of physical activity and prostate cancer in male health professionals Cancer Res. 58 1998 5117 5122
107. Giovanucci E. Rimm E.B. Wolk A. Ascherio A. Stampfer M.J. Calcium and fructose intake in relation to risk of prostate cancer Cancer Res. 58 1998 442 447
108. Giovanucci E. Stampfer M.J. Krithivas K. Brown M. Dahl D. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer Proc. Natl. Acad. Sci. (USA) 94 1997 3320 3323
109. Gleason D.F. Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J. Urol. 111 1974 58 64
110. Glueck C.J. McMahon R.E. Bouquot J.E. Triplett D. Gruppo R. Wang P. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens J. Lab. Clin. Med. 130 1997 540 543
111. Goodlad R.A. Wright N.A. Epidermal growth factor (EGF) Baillieres Clin. Gastroenterol. 10 1996 33 47
112. Gregory C.W. Kim D. Ye P. D'Ercole A.J. Pretlow T.G. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft Endocrinology 140 1999 2372 2381
113. Griffiths K. Morton M.S. Denis L. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer Eur Urol. 35 1999 443 455
114. Griffiths K. Morton M.S. Nicholson R.I. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer Eur. Urol. 32 1997 24 40
115. Gross C. Stamey T. Hancock S. Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J. Ural. 159 1998 2035 2040
116. Guo Y. Kyprianou N. Overexpression of transforming growth factor (TGF) beta type II receptors restores TGF-beta 1 sensitivity and signalling in human prostate cancer cells Cell Growth Different. 9 1998 185 193
117. Guo Y. Jacobs S.C. Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-β 1) type I and type II receptors in human prostate cancer Int. J. Cancer. 71 1997 573 579
118. Gustaffson J.A. Ekman P. Pousette A. Snochowski M. Hogberg B. Demonstration of a prosgestin receptor in human benign prostatic hyperplasia and prostatic carcinoma Invest. Urol. 15 1978 361 366
119. Hakimi J.M. Rondinelli R.H. Schoenberg M.P. Barrack E.R. Androgen-receptor gene structure and function in prostate cancer World J. Urol. 14 1996 329 337
120. Hanstein B. Liu H. Yancisin M.C. Brown M. Functional analysis of novel estrogen receptor-β isoforms Mol. Endocrinol. 13 1999 129 137
121. Hakimi J.M. Schoenberg M.P. Rondinelli R.H. Piantadosi S. Barrack E.R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer Clin. Cancer Res. 3 1997 1599 1608
122. Hanchette C.L. Schwartz G.G. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation Cancer 70 1992 2861 2869
123. Hardy D.O. Scher H.L. Bogenreider T. Sabbatini P. Zhang Z.F. Androgen receptor CAG repeat lenghts in prostate cancer: Correlation with age of onset J. Clin Endocrinol. Metab. 81 1996 4400 4405
124. Harper M.E. Goddard L. Glynne-Jones E. Peeling W.B. Griffiths K. Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumors Eur. J Cancer. 31A 1995 1492 1497
125. Harper M.E. Sibley P.E. Francis A.B. Nicholson R.I. Griffiths K. Immunocytochemical assay for estrogen receptors applied to human prostatic tumors Cancer Res. 46 1986 4288s 4290s
126. Hartman T.J. Albanes D. Rautalahti M. Tangrea J.A. Virtamo J. Physical activity and prostate cancer in the Alpha-tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland) Cancer Causes Control 9 1998 11 18
127. 3 are mediated through the genomic signalling pathway Endocrinology 137 1996 1554 1561
128. Hedlund P.O. Jacobsson H. Vaage S. Hahne B. Sandin T. Treatment of high-grade, high stage prostate cancer with estramustine phosphate or diethylstibesterol. A double-blind study. The SPCC-1 Study Group Scandinavian Prostate Cancer Group. Scand. J. Urol. Nephrol. 31 1997 167 172
129. Heshmat M.Y. Kaul L. Kovi J. Jackson M.A. Jackson A.G. Nutrition and prostate cancer: A case-control study Prostate 6 1985 7 17
130. Hess R.A. Bunick D. Lee K. Bahr J. Taylor J.A. A role for oestrogens in the male reproductive system Nature 390 1997 509 512
131. Hiramatsu M. Maehara I. Orikasa S. Sasano H. Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma Histopathology 28 1996 163 168
132. Hobisch A. Culig Z. Radmayr C. Bartsch G. Klocker H. Hittmair A. Distant metastasis from prostatic carcinoma express androgen receptor protein Cancer Res. 55 1995 3068 3072
133. Hobisch A. Culig Z. Radmayr C. Bartsch G. Mocker H. Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer Prostate 28 1996 129 135
134. Hobisch A. Hittmair A. Daxenbichler G. Wille S. Radmayr C. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors J. Pathol. 182 1997 336 356
135. Hofer D.R. Sherwood E.R. Bromberg W.D. Mendelsohn J. Lee C. Kozlowski J.M. Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor alpha Cancer Res. 51 1991 2780 2785
136. Hoosein N.M. Boyd D.D. Hollas W.J. Mazar A. Henkin J. Chung L.W. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines Cancer Commun. 3 1991 255 264
137. Hsieh T. Wu J.M. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1 alpha, 25 dihydroxyvitamin D3 in androgen responsive LNCaP cells Biochem. Biophys. Res. Commun. 235 1997 539 544
138. Hsieh T.Y. Ng C.Y. Mallouh C. Tazaki H. Wu J.M. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha, 25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells Biochem. Biophys. Res. Commun. 223 1996 141 146
139. Huggins C. Hodges C.V. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 297
140. Hyder S.M. Chiapetta C. Stancel G.M. Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements Biochem. Pharmacol. 57 1999 597 601
141. Hwa V. Tomasini-Sprenger C. Bermejo A.L. Rosenfeld R.G. Plymate S.R. Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells J. Clin. Endocrinol. Metab. 83 1998 4355 4362
142. Inoue K. Chikazawa M. Karashima T. Iiyama T. Kamada M. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma Acta Medica Okayama 52 1998 305 310
143. Irvine R.A. Yu M.C. Ross R.K. Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer Cancer Res. 55 1995 1937 1940
144. Ittman M. Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate J. Urol. 157 1997 351 356
145. Iwamura M. Sluss P.M. Casamento J.B. Cockett A.T. Insulin-like growth factor 1: Action and receptor characterization in human prostate cancer cell lines Prostate 22 1993 243 252
146. Jakowlew S.B. Moody T.W. Mariano J.M. Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation Anticancer Res. 17 1997 1849 1860
147. Jones H.E. Eaton C. Barrow D. Dutkowski C. Griffiths K. Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostate cell lines Prostate 30 1997 174 182
148. Jungwirth A. Galvan G. Pinski J. Halmos G. Szepeshazi K. Luteinizing hormonereleasing hormone antagonis Cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice Prostate 32 1997 164 172
149. Jungwirth A. Pinski J. Galvan G. Halmos G. Szepeshazi K. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II Eur. J. Cancer 33 1997 1141 1148
150. Katzenellenbogen J.A. O'Mally B.W. Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones Mot. Endocrinol. 10 1996 119 131
151. Khalid B.A. Nurshireen A. Rashidah M. Zainal B.Y. Roslan B.A. Mahamooth Z. Steroid hormone receptors in prostatic hyperplasia and prostatic carcinoma Med. J. Malaysia 45 1990 148 153
152. Kim I.Y. Ahn H.J. Lang S. Oefelein M.G. Oyasu R. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients Clin. Cancer Res. 4 1998 1625 1630
153. Kim I.Y. Zelner D.J. Sensibar J.A. Ahn H.J. Park L. Modulation of sensitivity to transforming growth factor beta 1 (TGF-β 1) and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone Exp. Cell. Res. 222 1996 103 110
154. Kim I.Y. Ahn H.J. Zelner D.J. Shaw J.W. Sensibar J.A. Genetic change in transforming growth factor beta (TGF-β) receptor type I gene correlates with insensitivity to TGF-β 1 in human prostate cancer cells Cancer Res. 56 1996 44 48
155. Kimura G. Kasuya J. Giannini S. Honda Y. Mohan S. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU-145, and PC-3 cells Int. J. Urol. 3 1996 39 46
156. Kiningham R.B. Physical activity and the primary prevention of cancer Prim Care 25 1998 515 536
157. Kitahara S. Yoshida K. Ishizaka K. Kageyama Y. Kawakami S. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist Endocr J. 44 1997 527 532
158. Klocker H. Neuschmid-Kaspar F. Culig Z. Cato A.C. Hobisch A. Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma Urol. Int. 54 1995 2 5
159. Knabbe C. Kellner U. Schmahl M. Voigt K.D. Growth factors in human prostate cancer cells: Implications for an improved treatment of prostate cancer J. Steroid Biochem. Mol. Biol. 40 1991 185 192
160. Koivisto P.A. Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer J. Pathol. 187 1999 237 241
161. Koivisto P. Visakorpi T. Kallioniem O. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer Scand. J. Clin. Lab. Invest. Suppl. 226 1996 57 64
162. Koivisto P. Kononen J. Palmberg C. Tammela T. Hyytinen E. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res. 57 1997 314 319
163. Kokontis J. Takakura K. Hay N. Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation Cancer Res. 54 1994 1566 1573
164. Konishi N. Nakaoka S. Hiasa Y. Kitahori Y. Oshima M. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy Oncology 50 1993 259 263
165. Krieg M. Nass R. Tunn S. Effect of ageing on endogenous level of 5-alphadihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate J. Clin. Endocrinol. Metab. 77 1993 375 381
166. Kruithof-Dekker T.G. Tetu B. Janssen P.J. Van der Kwast T.H. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy J. Urol. 156 1996 1194 1197
167. Kubota Y. Shuin T. Uemura H. Fujinami K. Miyoto H. Tumor suppressor gene p53 mutations in human prostate cancer Prostate 27 1995 18 24
168. Kuil C.W. Brinkmann A.O. Androgens, antiandrogens and androgen receptor abnormalities Eur. Urol. 29 1996 78 82
169. Kuiper G.G. Brinkmann A.O. Phosphotryptic peptide analysis of the human androgen receptor: Detection of a hormone-induced phosphopeptide Biochemistry 34 1995 1851 1857
170. Kuiper G.G. Carlsson B. Grandien K. Enmark E. Häggblad J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology 138 1997 863 870
171. Kuiper G.G. de Ruiter P.E. Brinkmann A.O. Androgen receptor heterogeneity in LNCaP cells is caused by a hormone independent phosphorylation step J. Steroid Biochem. Mol. Biol. 41 1992 697 700
172. Kuiper G.G. De Ruiter P.E. Trapman J. Boersma W.J. Grootegoed J-A. Brinkman A.O. Localization and hormonal stimulation of phophorylation sites in the LNCaP-cell androgen receptor Biochem. J. 291 1993 95 101
173. Kuiper G.G. Enmark E. Pelto-Huikko M. Nilsson S. Gustaffson J.-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary Proc. Natl. Acad. Sci. (USA) 93 1996 5925 5930
174. Kuiper G.G. Lemmen J.G. Carlsson B. Corton J.C. Sage S.H. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β Endocrinology 13 1998 4252 4263
175. Kumar V.L. Majumder P.K. Gujral S. Kumar V. Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate Cancer Lett. 134 1998 177 180
176. Kumar V.L. Wadhwa S.N. Kumar V. Farooq A. Androgen, estrogen, and progesterone receptor content and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate J. Surg. Oncol. 44 1990 122 128
177. Lamharzi N. Halmos G. Jungwirth A. Schally A.V. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice International. J. Oncol. 13 1998 429 435
178. Lamm M.L. Sintich S.M. Lee C. A proliferative effect of transforming growth factor-betal on a human prostate cancer cell line, TSU-Pr1 Endocrinology 139 1998 787 790
179. Landstrom M. Eklov S. Colosetti P. Nilsson S. Damber J.E. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-β 1 and its type-I and type-11 receptors Int. J. Cancer 67 1996 573 579
180. Latil A. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions Cancer Res. 57 1997 1058 1062
181. Leav I. McNeal J.E. Ziar J. Alroy J. The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions Human Pathol. 29 1998 668 675
182. Leblanc E.S. Laws A. Benefits and risks of third-generation oral contraceptives J. Gen. Intern. Med. 14 1999 625 632
183. Lepor H. Baumann M. Shapiro E. Binding and functional properties of doxazosin in the human prostate adenoma and canine brain Prostate 16 1990 29 38
184. Li S.-L. Goko H. Xu Z.-D. Kimura G. Sun Y. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder and paraglioma tumors Cell Tissue Res. 291 1998 469 479
185. Lippman M. Bolan G. Huff K. The effects of estrogens and antiestrogens on hormoneresponsive human breast cancer in long-term tissue culture Cancer Res. 36 1976 4595 4601
186. Lipset M.B. Interaction of drugs, hormones and nutrition in the causes of cancer Cancer 43 1979 1967 1981
187. Lloyd S.N. McClinton S. Brown I.L. Miller I.D. Kirk D. Epidermal growth factor receptor, nuclear proliferation antigen and interleukin-2 receptor expression in prostatic cancer J. Clin. Lab. Immunol. 32 1990 55 58
188. Longmore L. Foley J.P. Rozanski T.A. Higgins B. Thompson I.M. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression South. Med. J. 91 1998 573 575
189. Lucia M.S. Anzano M.A. Slayter M.V. Anver M.R. Green D.M. Chemopreventive acitvity of tamoxifen, N-(4-hydroxyphenyl)retamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate Cancer Res. 55 1995 5621 5627
190. Lui X.H. Wiley H.S. Meikle A.W. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGF-α receptor J. Clin. Endocrinol. Metab. 77 1993 1472 1478
191. Luke M.C. Coffey D.S. Human androgen receptor binding to the androgen response element of prostate specific antigen J. Androl. 15 1994 41 51
192. Luke M.C. Coffey D.S. The male sex accessory tissues: Structure, androgen action, and physiology E. Knobil J.D. Niell The Physiology of Reproduction Vol. 1 1994 Raven Press New York 1435 1488
193. Lundgren R. Nordle O. Josefsson K. Immediate estrogen or estramustine phophate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: A randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group J. Urol. 153 1995 1580 1586
194. MacLean H.E. Warne G.L. Zajac J.D. Localization of functional domains in the androgen receptor J. Steroid Biochem. Mol. Biol. 62 1997 233 242
195. Maddy S.Q. Chisholm G.D. Busuttil A. Habib F.K. Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumor Br J. Cancer 60 1989 41 44
196. Magi-Galluzzi C. Xu X. Hlattky L. Hahnfeldt P. Kaplan L. Heterogeneity of androgen receptor content in advanced prostate cancer Mod. Pathol. 10 1997 839 845
197. Magoha G.A. Effect of ageing on androgen levels in elderly males East Aft. Med. J. 74 1997 642 644
198. Mahler C. Verhelst J. Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer Clin. Pharmacokinet. 34 1998 405 417
199. Majumder P.K. Wadhwa S.N. Kumar V.L. Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate Urol. Int. 59 1997 231 235
200. Manes S. Llorente M. Lacalle R.A. Gomez-Mouton C. Kremer L. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells J. Biol. Chem. 274 1999 6935 6945
201. Marelli M.M. Moretti R.M. Dondi D. Limonta P. Motta M. Effects of LH-RH agonists on the growth of human prostate tumor cells: “ In vitro ” and “ in vivo ” studies Arch. Ital. Urol. Androl. 69 1997 257 263
202. Marelli M.M. Moretti R.M. Dondi D. Motta M. Limonta P. Luteinizing hormonereleasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells Endocrinology 140 1999 329 334
203. 3H]estradiol binding site antagonists: Inhibition of normal and malignant prostate cell growth and proliferation Int. J. Oncol. 12 1998 1127 1135
204. Markwalder R. Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: Relation to neopasic transformation Cancer Res. 59 1999 1152 1159
205. Matsubara A. Kan M. Feng S. McKeehan W.L. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2 Cancer Res. 58 1998 1509 1514
206. Maygarden S.J. Strom S. Ware J.L. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic adenocarcinoma, prostatic intraepithelia neoplasia, and benign hyperplasia Arch. Pathol. Lab. Med. 116 1992 269 273
207. McInerney E.M. Weiss K.E. Sun J. Mosselman S. Katzenellenbogen B.S. Transcription activation by the human estrogen receptor subtype P (ERP) studied with ERP and ERα receptor chimeras Endocrinology 139 1998 4513 4522
208. McLeod D.G. Crawford E.D. DeAntoni E.P. Combined androgen blockade: The gold standard for metastatic prostate cancer Eur Urol. 32 1997 70 77
209. Mellon K. Thompson S. Charlton R.G. Marsh C. Robinson M. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate J. Urol. 147 1992 496 499
210. Messina M.J. Legumes and soybeans: Overview of their nutritional profiles and health effects Am. J. Clin. Nutr. 70 1999 439S 450S
211. Meyer F. Baitrati L. Fradet Y. Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer Nutr Cancer 29 1997 120 126
212. Mitra S.P. Carraway R.E. Synergistic effects of neurotensin and beta-adrenergic agonist on 3,5-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells Biochem. Pharmacol. 57 1999 1391 1397
213. Miyake H. Hara I. Yamanaka K. Gohji K. Arakawa S. Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer Prostate 39 1999 123 129
214. Miyamoto K.K. McSherry S.A. Dent G.A. Sar M. Wilson E.M. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue J. Urol. 149 1993 1015 1019
215. Mobbs B.G. Johnson I.E. Lui Y. Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and malignant human prostatic tissue by radioligand binding and enzyme-immunoassays Prostate 16 1990 235 244
216. Mobbs B.G. Johnson I.E. DeSombre E.R. Toth J. Hughes A. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone Cancer Res. 47 1987 2645 2651
217. Mohanam S. Gladson C.L. Rao C.N. Rao J.S. Biological significance of the expression of urokinase-type plaminogen activator receptors (uPARs) in brain tumors Front. Biosci. 4 1999 D178 D187
218. Montano M.M. Jaiswal A.K. Katzenellenbogen B.S. Transcriptional regulation of the muna quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β J. Biol. Chem. 273 1998 25443 25449
219. Morley J.E. Kaiser F.E. Perry H.M. Patrick P. Morley P.M. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men Metabolism 46 1997 410 413
220. Morris G.L. Dodd J.G. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines J. Urol. 143 1990 1272 1274
221. Morton M.S. Chan P.S.F. Cheng C. Blacklock N. Matosferreira A. Lignans and isoflavones in plasma and prostatic fluid in men—Samples from Portugal, Hong Kong and the United Kingdom Prostate 32 1997 122 128
222. Mosselman S. Polman J. Dijkema R. ERP: Identification and characterization of a novel human estrogen receptor FEBS Lett. 392 1996 49 53
223. Moyad M.A. Pienta K.J. Montie J.E. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naïve disease Urology 54 1999 319 324
224. Mulder E. van Loon D. de Boer W. Schuurmans A.L. Bolt J. Mechanism of androgen action: recent observations on the domain structure of androgen receptors and the induction of EGF-receptors by androgens in prostate tumor cells J. Steroid Biochem. 32 1989 151 156
225. Mustjoki S. Alitalo R. Stephens R.W. Vaheri A. Plasminogen in human leukemia and in normal hemapoietic cells APMIS 107 1999 144 149
226. Myers R.B. Kudlow J.E. Grizzle W.E. Expression of transforming growth factor a, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia Mod. Pathol. 6 1993 733 737
227. Nativ O. Umehara T. Colvard D.S. Themeau T.M. Farrow G.M. Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer Eur. Urol. 32 1997 96 99
228. Nazareth L.V. Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway J. Biol. Chem. 271 1996 19900 19907
229. Newmark J.R. Hardy D.O. Tonb D.C. Carter B.S. Epstein J.I. Androgen receptor gene structure mutations in human prostate cancer Proc. Natl. Acad. Sci. (USA) 89 1992 6319 6323
230. Niederberger C. Computational tools for the modern andrologist J. Androl. 17 1996 462 466
231. Nieh P.T. Withdrawal phenomenon with the antiandrogen casodex J. Urol. 153 1995 1070 1072
232. Discussion Nieh P.T. Withdrawal phenomenon with the antiandrogen casodex J. Urol. 153 1995 1072 1073
233. Nielsen F.C. The molecular and cellular biology of insulin-like growth factor II Prog. Growth Factor Res. 4 1992 257 290
234. Nieuwoudt L.B. van Aswegen C.H. Böckmann H.I. van der Merwe C.A. du Plessis D.J. Correlation between the macromolecular effects of estradiol and cathecolestradiols and the total prostatic cathecolestrogen concentration Clin. Physiol. Biochem. 8 1990 231 237
235. Norman A.W. Roth J. Orci L. The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins) Endocr Rev. 3 1982 331 366
236. Nunez E.A. Free fatty acids as modulators of the steroid hormone message Prostaglandins Leak. Essent. Fatty Acids 48 1993 63 70
237. Ogawa S. Inoue S. Watanabe T. Hiroi H. Orimi A. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro Biochem. Biophys. Res. Commun. 243 1998 122 126
238. Oliviera S.A. Christos P.J. The epidemiology of physical activity and cancer Ann. N. Y. Acad. Sci. 833 1997 79 90
239. Oliviera S.A. Lee I.M. Is exercise beneficial in the prevention of prostate cancer? Sports Med. 23 1997 271 278
240. Otto A.M. A one minute pulse of estradiol to MCF-7 breast cancer cells changes estrogen receptor binding properties and commits cells to induce estrogenic responses J. Steroid Biochem. Mot. Biol. 54 1995 39 46
241. Pace P. Taylor J. Suntharalingam S. Coombes R.C. Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha J. Clin. Endocrinol. Metab. 82 1997 3509 3512
242. Patisaul H.B. Whitten P.L. Young L.J. Regulation of estrogen receptor beta mRNA in the brain: opposite effects of 17β-estradiol and the phytoestrogen, cournestrol Brain Res. Mol. Brain Res. 67 1999 165 171
243. Pasquali D. Thaller C. Eichele G. Abnormal level of retinoic acid in prostate cancer tissues J. Clin. Endocrinol. Metab. 81 1996 2186 2191
244. 3 on primary cultures of human prostatic cells Cancer Res. 54 1994 805 810
245. Peehl D.M. Cellular biology of prostatic growth factors Prostate 6 1996 74 78
246. Pemrick S.M. Lucas D.A. Grippo J.F. The retinoid receptors Leukemia 8 1994 S1 S10
247. Pennie W.D. Aldridge T.C. Brooks K.N. Differential activation by xenoestrogens of ER alpha and ER beta when linked to different response elements J. Endocrinol. 158 1998 R11 R14
248. Pentyala S. Whyard T.C. Waltzer W.C. Meek A.G. Hod Y. Androgen induction of urokinase gene expression in LNCaP cells is dependent on their interaction with the extracellular matrix Cancer Lett. 130 1998 121 126
249. Perez M. Regan T. Pflung B. Lynch J. Djakiew D. Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate Prostate 30 1997 274 279
250. Pfung B. Djakiew D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death Mol. Carcinog. 23 1998 106 114
251. Pfung B.R. Onoda M. Lynch J.H. Djakiew D. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue of expression in four human metastatic tumor cell lines Cancer Res. 52 1992 5403 5406
252. Pietrzkowski Z. Mulholland G. Gomella L. Jameson B.A. Wernicke D. Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogs of insulin-like growth factor 1 Cancer Res. 53 1993 1102 1106
253. 3 receptors: structure and function in transcription Annu. Rev. Nutr. 11 1991 189
254. Pincus S.M. Mulligan T. Iranmanesh A. Gheorghui S. Godschalk M. Veldhuis J.D. Older males secrete luteinizing hormone and testosterone more irregularly, andjointly more asynchronously than younger males Proc. Natl. Acad. Sci. (USA) 93 1996 14100 141055
255. Plas E. Carroll V.A. Jilch R. Mihaly J. Vesely M. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer Int. J Cancer 78 1998 320 325
256. Plymate S.R. Bae V.L. Maddison L. Quinn L.S. Ware J.L. Reexpression of the type I insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells Endocrinology 138 1997 1728 1735
257. Prins G.S. Marmer M. Woodham C. Chang W. Kuiper G. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats Endocrinology 139 1998 874 883
258. Prins G.S. Sklarew R.J. Perschuck L.P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy J. Urol. 159 1998 641 649
259. Putz T. Culig Z. Eder I.E. Nessler-Menardi C. Bartsch G. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines Cancer Res. 59 1999 227 233
260. Rabbani S.A. Xing R.H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies Int. J. Oncol. 12 1998 911 920
261. Ravenna L. Lubrano C. Di Silverio F. Vacca A. Felli M.P. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP Prostate 26 1995 290 298
262. Rechler M.M. Nissley S.P. Insulin-like growth factor (IGF)/somatomedin receptor subtypes: structure, function and relationships to insulin receptors and IGF carrier proteins Horm. Res. 24 1986 152 159
263. Reichart J.K. Makridakis N. Henderson B.E. Yu M.C. Pike M.C. Ross R.K. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk Cancer Res. 55 1995 3973 3975
264. Reinikainen P. Palvimo J.J. Janne O.A. Effects of mitogens on androgen receptormediated transactivation Endocrinology 137 1996 4351 4357
265. Ridings J. Macardle P.J. Byard R.W. Skinner J. Zola H. Cytokine receptor expression by solid tumors Ther Immunol. 2 1995 67 76
266. Rivas C.I. Vera J.C. Delgrado-Lopez F. Heany M.L. Guaiquil V.H. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer Blood 91 1998 1037 1043
267. Roberson K.M. Penland S.N. Padilla G.M. Selvan R.S. Kim C.S. Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells Cell Growth Differ. 8 1997 101 111
268. Robertson C.N. Roberson K.M. Padilla G.M. O'Brien E.T. Cook J.M. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells J. Natl. Cancer Inst. 88 1996 908 917
269. Roklin O.W. Griebling T.L. Karassina N.V. Raines M.A. Cohen M.B. Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface Anticancer Res. 16 1996 557 563
270. Rosmond R. Bjorntorp P. The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure Int. J. Obes. Relat. Metab. Disord. 22 1998 1184 1196
271. Ross R.K. Bernstein L. Lobo R.A. Shimizu H. Stanczyk F.Z. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males Lancet 339 1992 887 889
272. Royella M. De Miguel M.P. Bethencourt F.R. Snachez-Chapado M. Fraile B. Paniagua R. Transforming growth factor beta 1 and its receptors types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma Growth Factors 16 1998 101 110
273. Rubenstein M. Mirochnik Y. Chou P. Guinan P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides Meth. Find. Exp. Clin. Pharmacol. 20 1998 825 831
274. Sak S.D. Orhan D. Yaman O. Tulunay O. Ozdiler E. Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy Urol. Int. 59 1997 50 52
275. s2 Sanchez-Visconti G. Herrero L. Rabadan M. Pereira I. Ruiz-Torres A. Ageing and prostate: Age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer Mech. Ageing Dev. 82 1995 19 29
276. Santibanez J.F. Navarro A. Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines Anticancer Res. 17 1997 1199 1204
277. Savarese D.M. Valinsky H. Quesenberry P. Savarese T. Expression and function of colony-stimulating factors and their receptors in human prostate cell lines Prostate 34 1998 80 91
278. Scher H.I. Kelly W.K. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer J. Clin. Oncol. 11 1993 1566 1572
279. Scher H.I. Sarkis A. Reuter V. Cohen D. Netto G. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms Clin. Cancer Res. 1 1995 545 550
280. Schrader M. Bendik J. Becker-Andre M. Carlberg C. Interaction between retinoic acid and retinoic acid and vitamin D signalling pathways J. Biol. Chem. 268 1993 17830 17836
281. Schuurmans A.L. Bolt J. Mulder E. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP) Mol. Cell. Endocrinol. 60 1988 101 104
282. Schuurmans A.L. Bolt J. Mulder E. Androgen receptor-mediated growth and epidermal growth factor receptor induction in the human prostate cell line LNCaP Urol. Int. 44 1989 71 76
283. Schuurmans A.L. Bolt J. Veldscholte J. Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion J. Steroid Biochem. Mol. Biol. 37 1990 849 853
284. Schuurmans A.L. Bolt J. Voorhorst M.M. Blankenstein R.A. Mulder E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids Int. J. Cancer 42 1988 917 922
285. 3 and prostate cancer cell proliferation in vivo Urology 46 1995 365 369
286. Schwartz G.G. Wang M.H. Zang M. Singh R.K. Siegel G.P. 1α,25-Dihydroxivitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells Cancer Epidemiol. Biomarkers Prev. 6 1997 727 732
287. Seghal I. Bailey P.A. Thompson T.C. Transforming growth factor beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro Cancer Res. 56 1996 3359 3365
288. Seghal I. Bailey P.A. Hitzemann K. Pittelkow M.R. Maihle N.J. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells Mol. Biol. Cell. 5 1994 339 347
289. Sella A. Flex D. Sulkes A. Baniel J. Antiandrogen withdrawal syndrome with cyproterone acetate Urology 52 1998 1091 1093
290. Sherwood E.R. Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate World J. Urol. 13 1995 290 296
291. Shibata A. Whittemore A.S. Genetic predisposition to prostate cancer: possible explainations for ethnic differences in risk Prostate 32 1997 65 72
292. Shughrue P.J. Lane M.V. Scrimo P.J. Merchenthaler I. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract Steroids 63 1998 498 504
293. 3 Endocrinology 136 1995 20 26
294. s2 Stanford J.L. Just J.J. Gibbs M. Wicklund K.G. Neal C.L. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk Cancer Res. 57 1997 1194 1198
295. s2 Steiner M.S. Transforming growth factor-β and prostate cancer World J. Urol. 13 1995 329 336
296. s2 Stephens F.O. Phytoestrogens and prostate cancer: Possible preventative role Med. J. Austral. 167 1997 138 140
297. s2 Stephens R.W. Nielsen H.J. Christensen I.J. Thorlacius-Ussing O. Sorenson S. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis J. Nod. Cancer Inst. 91 1999 869 874
298. s2 Stone N.N. Fair W.R. Fishman J. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia Prostate 9 1986 311 318
299. s2 Story M.T. Regulation of prostate growth by fibroblast growth factors World J. Urol. 13 1995 297 305
300. s2 Strom S.S. Yamamura Y. Duphorne C.M. Spitz M.R. Babaian R.J. Phytoestrogen intake and prostate cancer: A case-control study using a new database Nutr Cancer 33 1999 20 25
301. s2 Stubbs A.P. Murphy G.M. Wilkinson M.L. Isocratic high-performance liquid chromatographic measurement of optimal 5a-steroid reductase activity in Hep-G2 cells J. Chromatogr. 570 1991 293 299
302. s2 Sun J. Meyers M.J. Fink B.E. Rajendran R. Katzenellenbogen J.A. Katzenellenbogen B.S. Novel fgands that function as selective estrogens or antiestrogens for estrogen receptor-alpha of estrogen receptor-beta Endocrinology 140 1999 800 804
303. Suzuki H. Akakura K. Komiya A. Aida S. Akimoto S. Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome Prostate 29 1996 153 158
304. Suzuki H. Sato N. Watabe Y. Masai M. Seino S. Shimazaki J. Androgen receptor gene mutations in human prostate cancer J. Steroid Biochem. Mol. Biol. 46 1993 759 765
305. Taplin M.E. Bubley G.J. Shuster T.D. Frantz M.E. Spooner A.E. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N. Engl. J. Med. 332 1995 1393 1398
306. Tennant M.K. Thrasher J.B. Twomey P.A. Drivdahl R.H. Birnbaum R.S. Plymate S.R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-11 mRNA is increased in human prostate carcinoma compared to benign prostate epithelium J. Clin. Endocrinol. Metab. 81 1996 3774 3782
307. Tenover J.L. Testosterone and the ageing male J. Androl. 18 1997 103 106
308. Tewari A. Narayan P. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks J. Urol. 160 1998 430 436
309. Tilley W.D. Buchanan G. Hickey T.E. Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence Clin. Cancer Res. 2 1996 277 285
310. Tillotson J.K. Rose D.P. Density-dependent regulation of epidermal growth factor receptor expression in DU-145 human prostate cancer cells Prostate 19 1991 53 61
311. Tomic R. Damber J.E. Bergman B. Endocrine effects of oestrogen withdrawal in long-term treated patients with prostatic carcinoma Eur. Urol. 14 1988 6 8
312. Trachtenberg J. Innovative approaches to the hormonal treatment of advanced prostate cancer Eur. Urol. 32 1997 78 80
313. Tremblay G.B. Tremblay A. Labrie F. Giguere V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex Mol. Cell. Biol. 19 1999 1919 1927
314. Tseng-Crank J. Kost T. Goetz A. Hazum S. Roberson K.M. The alpha ICadrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types Br. J. Pharmacol. 115 1995 1475 1485
315. Tserotas K. Merino G. Andropause and the ageing male Arch. Andr. 40 1998 87 93
316. Turner T. Epps-Fung M.V. Kassis J. Wells A. Molecular inhibition of phospholipase c γ signalling abrogates DU-145 prostate tumor cell invasion Clin. Cancer Res. 3 1997 2275 2282
317. Turner T. Chen P. Goodly L.J. Wells A. EGF receptor signalling enhances in vivo invasiveness of DU-145 human prostate Clin. Exp. Metastasis 14 1996 408 418
318. U.S. Department of Health and Human Services Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Agency for Health Care Policy and Research Evidence Report/Technology Assessment 4 1999 1 6
319. Van Aswegen C.H. The effect of essential fatty acids on growth and urokinase-type plasminogen activator production on human prostate DU-145 cells Prostaglandins Leuk. Essent. Fatty Acids 55 1996 173 177
320. Van Aswegen C.H. Du Plessis D.J. A possible role for enzymes in tumor-cell invasion Med. Hyp. 48 1997 443 447
321. Van Aswegen C.H. Nieuwoudt L.B. Van Rensburg H.G.J. Steyn P.L. Du Plessis D.J. Estradiol and cathecolestradiols as possible genotoxic carcinogens Clin. Phys. Biochem. 7 1989 34 39
322. Van Laar J.H. Berrevoets C.A. Trapman J. Zegers N.D. Brinkmann A.O. Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells J. Biol. Chem. 266 1991 3734 3738
323. Vawer A. Rashbass J. The biological toolbox: A computer program for simulating basic biological and pathological processes Comput. Meth. Programs Biomed. 52 1997 203 211
324. Veldscholte J. Berrevoets C.A. Ris-Stalpers C. Kuiper G.G. Jenster G. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J. Steroid Biochem. Mol. Biol. 41 1992 665 669
325. Viljoen T.C. Van Aswegen C.H. Du Plessis D.J. Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid Prostate 27 1995 160 165
326. Visakorpi T. Kalloniemi O.P. Koivula T. Harvey J. Isola J. Expression of epidermal growth factor receptor and erbB2 (HER-2/Neu) oncoprotein in prostatic carcinomas Mod. Pathol. 5 1992 643 648
327. Volm M. Matters J. Koomagi R. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival Oncol. Rep. 6 1999 611 615
328. Von Eschenbach A. Ho R. Murphy G.P. Cunningham M. Lins N. American Cancer Society guideline for the early detection of prostate cancer: Update Cancer J. Clin. 47 1997 261 264
329. Walker A.R.P. Walker B.F. Tsotetsi N.G. Sebito C. Siwedi D. Walker A.D. Case-control study of prostate cancer in black patients in Soweto, South Africa Br. J. Cancer 65 1992 438 441
330. 3 analogue EB-1089 on a human prostate cancer cell line (PC-3) Br. J Urol. 80 1997 260 262
331. Wang Y.Z. Wong Y.C. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer Prostate 35 1998 165 177
332. Ware J.L. Growth factor network disruption in prostate cancer progression Cancer Metastasis Rev. 17 1999 443 447
333. Wernert N. Gerdes J. Loy V. Seitz G. Scherr O. Dhom G. Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis Virch. Arch. [A] 412 1988 387 391
334. Wikstrom P. Bergh A. Damber J.E. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment Urol. Res. 25 1997 103 111
335. Wikstrom P. Stattin P. Franck-Lissbrandt I. Damber J.E. Bergh A. Transforming growth factor beta 1 is associated with angiogenesis, metastasis, and poor outcome in prostate cancer Prostate 37 1998 19 29
336. Wilding G. The importance of steroid hormones in prostate cancer Cancer Surv. 14 1992 113 130
337. Willet W.C. Specific fatty acids and risks of breast and prostate cancer: Dietary intake Am. J Clin. Nutr. 66 1997 15635 15775
338. Williams R.H. Stapleton A.M. Yang G. Truong L.D. Rogers E. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study Clin. Cancer Res. 2 1996 635 640
339. Wilson J.D. The patogenesis of benign prostatic hyperplasia Am. J. Med. 68 1980 745 747
340. Wolk A. Mantrozoros C.S. Andersson S.-O. Bergstrom R. Signorello L.B. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case control study J. Natl. Cancer Inst. 90 1998 911 915
341. Xie H. Turner T. Wang M.H. Singh R.K. Siegal G.P. Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals Clin. Exp. Metastasis 13 1995 407 419
342. Yan G. Fukabori Y. McBride G. Nikolaropolous S. McKeehan W.L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy Mol. Cell Biol. 13 1993 4513 4522
343. Yeh S. Miyamoto H. Shima H. Chang C. From estrogen to androgen receptor: A new pathway for sex hormones in prostate Proc. Natl. Acad. Sci. (USA) 95 1998 5527 5532
344. Yeh S. Lin H.K. Kang H.Y. Thin T.H. Lin M.F. Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells Proc. Natl. Acad. Sci. (USA) 96 1999 5458 5463
345. Yeh S. Miyamoto H. Nishimura K. Kang H. Ludlow J. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells Biochem. Biophys. Res. Commun. 248 1998 361 367
346. 3 actions in LNCaP human prostate cancer are androgen dependent Endocrinology 138 1997 3290 3298
347. Zhou J.R. Gugger E.T. Tanaka T. Guo Y. Blackburn G.L. Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice J. Nutr. 129 1999 1628 1635
348. Zhou Z.X. Kempainen J.A. Wilson E.M. Identification of three proline-directed phosphorylation sites in the human androgen receptor Mol. Endocrinol. 9 1995 605
349. Zhu X. Liu J.P. Steroid-independent activation of androgen receptor in androgenindependent prostate cancer: A possible role for the MAP kinase signal transduction pathway? Mol. Cell. Endocrinol. 134 1997 9 14
350. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation Endocrinology 139 1998 1197 1207
351. Zhuang S.H. Schwartz G.G. Cameron D. Blumenstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines Mol. Cell. Endocrinol. 126 1997 83 90
352. Zi X. Grasso A.W. Kung H.J. Agarwal R. A flavonoid antioxidant, siIymarin, inhibits activation of erbB 1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells Cancer Res. 58 1998 1920 1929
353. Zolfaghardi A. Djakiew D. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-prl) line by inhibition of epidermal growth factor receptor function Prostate 28 1996 232 238